Clozapine Management in Schizophrenia Inpatients: A 5-Year Prospective Observational Study of Its Safety and Tolerability Profile
Renato de Filippis,1 Raffaele Gaetano,1 Georgios Schoretsanitis,2 Giuseppe Verde,1 Cesare Anthony Oliveti,3 John M Kane,2,4,5 Cristina Segura-Garcia,6 Pasquale De Fazio1 1Psychiatry Unit, Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy; 2The Zucker Hillside Hos...
Guardado en:
Autores principales: | de Filippis R, Gaetano R, Schoretsanitis G, Verde G, Oliveti CA, Kane JM, Segura-Garcia C, De Fazio P |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/036e476c5c7d4bd89f34c75873edfdb2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Reduction in Absolute Neutrophil Counts in Patient on Clozapine Infected with COVID-19
por: Fitri Fareez Ramli, et al.
Publicado: (2021) -
Clinical predictors of response to clozapine in Tunisian patients with treatment resistant schizophrenia
por: Amina Aissa, et al.
Publicado: (2022) -
Neuroleptic malignant syndrome and subsequent clozapine-withdrawal effects in a patient with refractory schizophrenia
por: Cheng MF, et al.
Publicado: (2016) -
Artesunate prevents rats from the clozapine-induced hepatic steatosis and elevation in plasma triglycerides
por: Li Y, et al.
Publicado: (2017) -
A case of schizophrenia comorbid for tetralogy of Fallot treated with clozapine: further considerations on a role for 22q.11.2 in the proneness for seizures
por: Kashiwagi H, et al.
Publicado: (2017)